# Effects of cAMP and CFTR modulation on apical fluid pH in human airway Calu‐3 cells

**Authors:** Jenny P. Nguyen, Nadia Milad, Jeremy A. Hirota

PMC · DOI: 10.14814/phy2.70747 · Physiological Reports · 2026-02-03

## TL;DR

This study shows that using cAMP and CFTR modulators can raise pH in airway cells, which may help treat respiratory diseases.

## Contribution

The study demonstrates that combining cAMP and CFTR modulators increases apical fluid pH more effectively than single treatments.

## Key findings

- Pharmacological interventions with cAMP and VX-770 significantly increased apical fluid pH.
- Combination treatments led to greater pH increases compared to single drug use.
- Modulating cAMP and CFTR may be a promising therapeutic strategy for ASL pH abnormalities.

## Abstract

The airway epithelium serves as the first line of defense against inhaled insults present in the external environment by acting as a physical barrier and through host defense mechanisms. Proper maintenance of these host defense mechanisms relies on the regulation of airway surface liquid (ASL) composition and properties, a process that is tightly controlled by various ion transporters, including the cystic fibrosis transmembrane conductance regulator (CFTR) protein. With evidence suggesting dysfunctional CFTR‐mediated bicarbonate secretion leads to airway acidification, resulting in impaired host defenses, there is increased interest in improving ASL pH. The aim of our study was to determine whether pharmacological interventions, via cAMP and CFTR modulators, lead to an increase in pH. Human airway epithelial (Calu‐3) cells were exposed to various combinations of cAMP and CFTR modulating agents to assess their effectiveness at elevating apical base secretions (apical fluid) pH. Our results show that pharmacological interventions with cAMP elevating agents and CFTR modulator VX‐770 led to significant increases in pH, with combinations leading to greater increases compared to single drug interventions. Our study suggests that cAMP and CFTR modulation has potential as a therapeutic strategy for elevating ASL pH and may be beneficial for respiratory diseases with ASL abnormalities.

## Linked entities

- **Proteins:** CFTR (CF transmembrane conductance regulator)
- **Chemicals:** cAMP (PubChem CID 6076), VX-770 (PubChem CID 16220172)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** PDE4A (phosphodiesterase 4A) [NCBI Gene 5141] {aka DPDE2, PDE4, PDE46}, CFTR (CF transmembrane conductance regulator) [NCBI Gene 403154] {aka ABCC7}, SLC26A4 (solute carrier family 26 member 4) [NCBI Gene 5172] {aka DFNB4, EVA, PDS, TDH2B}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, ANO1 (anoctamin 1) [NCBI Gene 55107] {aka DOG1, INDMS, MYMY7, ORAOV2, TAOS2, TMEM16A}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ABCC4 (ATP binding cassette subfamily C member 4 (PEL blood group)) [NCBI Gene 10257] {aka MOAT-B, MOATB, MRP4}, CFTR (CF transmembrane conductance regulator) [NCBI Gene 1080] {aka ABC35, ABCC7, CF, CFTR/MRP, MRP7, TNR-CFTR}, ATP12A (ATPase H+/K+ transporting non-gastric alpha2 subunit) [NCBI Gene 479] {aka ATP1AL1, H-K-ATPase, HK}
- **Diseases:** CF (MESH:D003550), CF lung disease (MESH:C563237), respiratory diseases (MESH:D012140), COPD (MESH:D029424), airway infections (MESH:D007239), inflammation (MESH:D007249), airway obstruction (MESH:D000402), lung adenocarcinoma (MESH:D000077192), ASL abnormalities (MESH:D010534), recessive genetic disease (MESH:D030342), loss of pulmonary function (OMIM:608852)
- **Chemicals:** GlyH-101 (MESH:C548779), penicillin (MESH:D010406), Ivacaftor (MESH:C545203), CO2 (MESH:D002245), phosphate (MESH:D010710), Cl- (MESH:D002713), HCO3 - (MESH:D001639), Alpha-Minimum Essential medium (-), lumacaftor (MESH:C569105), HEPES (MESH:D006531), PBS (MESH:D007854), CaCl2 (MESH:D002122), DMSO (MESH:D004121), elexacaftor (MESH:C000629074), MgCl2 (MESH:D015636), RF (MESH:C424423), chloride (MESH:D002712), ISO (MESH:D007545), carbachol (MESH:D002217), MK-571 (MESH:C059141), NaCl (MESH:D012965), tezacaftor (MESH:C000625213), K+ (MESH:D011188), FSK (MESH:D005576), sodium (MESH:D012964), streptomycin (MESH:D013307), KCl (MESH:D011189)
- **Species:** Mustela putorius furo (black ferret, subspecies) [taxon 9669], Sus scrofa (pig, species) [taxon 9823], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 508del CFTR, G551D
- **Cell lines:** Calu-3 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0609), HTB- — Mus musculus (Mouse), Hybridoma (CVCL_A8FQ)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12868389/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12868389/full.md

## References

79 references — full list in the complete paper: https://tomesphere.com/paper/PMC12868389/full.md

---
Source: https://tomesphere.com/paper/PMC12868389